复发或转移性胃肠间质瘤的肿瘤细胞减灭术:单中心回顾性分析
该单中心回顾性队列纳入89例复发和(或)转移性GIST患者,比较CRS联合TKI与仅TKI治疗。CRS联合TKI组中位总生存优于仅TKI组(102.0个月比65.5个月,P<0.05);初次复发转移时直接CRS联合伊马替尼的PFS优于单用伊马替尼(67.0个月比24.0个月,P<0.05),但一线伊马替尼失败后两组PFS无差异(P=0.330)。完全细胞减灭是PFS独立预后因素。
要点
- 复发或转移性GIST行CRS联合TKI较仅TKI改善中位总生存(102.0个月比65.5个月,P<0.05)。
- 初次复发转移时直接CRS联合伊马替尼的PFS优于单用伊马替尼(67.0个月比24.0个月,P<0.05)。
- 一线伊马替尼失败后CRS联合TKI与仅TKI的PFS无统计学差异(P=0.330)。
核心结论
- CRS可改善复发或转移性GIST患者的预后,尤其在初次发现复发和转移时。
- 肿瘤细胞减灭程度是PFS的独立预后因素(HR=5.804,95%CI:1.841~18.296,P<0.01)。
研究设计与样本
- 单中心回顾性队列研究,纳入2007年12月至2024年8月中山大学附属第六医院89例复发和(或)转移性GIST患者。
- 男性67例、女性22例,年龄(56.0±11.9)岁(范围:26~79岁)。
- CRS联合TKI组51例,仅TKI治疗组38例。
主要发现
- CRS联合TKI组中位总生存102.0个月,优于仅TKI组的65.5个月(P<0.05),经逆概率加权法调整后获益保持稳定。
- 初次复发和(或)转移时直接CRS联合伊马替尼的PFS为67.0个月,优于仅伊马替尼的24.0个月(P<0.05)。
- 一线伊马替尼治疗失败后,CRS联合TKI与仅TKI的中位PFS差异无统计学意义(P=0.330)。
- 51例接受CRS患者中47例(74.6%)达到完全肿瘤细胞减灭(CC0/1)。
- CC0/1组中位PFS 22.0个月(95%CI:18.0~67.0个月)优于CC2/3组的13.0个月(95%CI:3.0个月至未达到),P<0.01;CC0/1组中位总生存未达到(95%CI:85.6个月至未达到),优于CC2/3组的31.5个月(95%CI:25.1个月至未达到),P<0.01。
关键数值与推荐
- 完全肿瘤细胞减灭(CC0/1)定义为达到完全细胞减灭,51例CRS患者中47例(74.6%)实现。
- 术后Clavien-Dindo并发症分级系统Ⅲ、Ⅳ级并发症发生率为17.5%(11/63),无围手术期死亡。
临床怎么用
- 对初次发现复发和(或)转移的GIST患者,可考虑直接行CRS联合伊马替尼治疗以改善PFS。
- CRS应尽可能达到完全肿瘤细胞减灭(CC0/1),因其与更优的PFS和总生存相关。
- 一线伊马替尼治疗失败后,CRS联合TKI对比仅TKI未见PFS获益,决策需个体化。
局限性
- 本研究为单中心回顾性队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy of cytoreductive surgery (CRS) combined with tyrosine kinase inhibitor(TKI) for the treatment of recurrent and metastatic gastrointestinal stromal tumor(GIST) and to identify the prognostic factors. Methods: This is a retrospective cohort study. A total of 89 patients diagnosed with recurrent and/or metastatic GIST at the Department of General Surgery,the Sixth Affiliated Hospital of Sun Yat-sen University from December 2007 to August 2024 were included. Among them,67 were male and 22 were female,with an age of (56.0±11.9)years (range: 26 to 79 years). Patients were divided into two groups based on whether CRS was performed: the CRS combined with TKI therapy group (51 patients) and the TKI therapy alone group(38 patients). Clinical and pathological data,as well as prognostic data,were compared between groups using independent sample t-test,Wilcoxon rank-sum test, χ2 test,or Fisher's exact test. Cox proportional hazards regression model was used for prognostic factor analysis. Results: The CRS combined with TKI therapy group demonstrated superior median overall survival compared to the TKI therapy alone group (102.0 months vs. 65.5 months,P<0.05),with benefits remaining stable after inverse probability weighting (IPTW). For patients with newly diagnosed recurrence and/or metastasis,upfront CRS combined with imatinib showed improved progression-free survival(PFS) compared to imatinib alone (67.0 months vs. 24.0 months,P<0.05). However,following first-line imatinib failure,there was no significant difference in PFS between CRS combined with TKI therapy and TKI therapy alone (P=0.330). Among the 51 patients who underwent CRS,47 patients (74.6%) achieved complete cytoreduction (CC0/1). The incidence of Clavien-Dindo grade Ⅲ to Ⅳ complications was 17.5%(11/63),with no perioperative mortality. Survival analysis revealed that the CC0/1 group had superior median PFS time(22.0 months (95%CI: 18.0 to 67.0 months) vs. 13.0 months (95%CI: 3.0 months to not reached),P<0.01) and median overall survival time(not reached (95%CI: 85.6 months to not reached) vs. 31.5 months (95%CI: 25.1 months to not reached), P<0.01) compared to the CC2/3 group. Multivariate Cox analysis indicated that the completeness of cytoreduction was an independent prognostic factor for PFS (HR=5.804,95%CI: 1.841 to 18.296, P<0.01). Conclusion: CRS can improve the prognosis of patients with recurrent or metastatic GIST, especially at its initial diagnosis. 目的: 探讨肿瘤细胞减灭术(CRS)联合酪氨酸激酶抑制剂(TKI)治疗复发和转移性胃肠道间质瘤(GIST)的效果及其预后因素。 方法: 本研究为回顾性队列研究。回顾性纳入2007年12月至2024年8月在中山大学附属第六医院诊断为复发和(或)转移性GIST的89例患者。男性67例,女性22例,年龄(56.0±11.9)岁(范围:26~79岁)。按照是否进行CRS治疗进行分组,其中CRS联合TKI治疗组51例,仅TKI治疗组38例。采用独立样本t检验、Wilcoxon秩和检验、χ2检验或Fisher确切概率法比较组间的临床和病理学资料及预后资料。采用Cox比例风险回归模型进行预后因素分析。 结果: CRS联合TKI治疗组的中位总体生存时间优于仅TKI治疗组(102.0个月比65.5个月,P<0.05),经逆概率加权法调整后获益保持稳定。初次发现复发和(或)转移时,直接行CRS联合伊马替尼治疗的无进展生存(PFS)时间较仅行伊马替尼治疗有优势(67.0个月比24.0个月,P<0.05);但在一线伊马替尼治疗失败后,CRS联合TKI治疗对比仅TKI治疗,中位PFS时间的差异无统计学意义(P=0.330)。在51例接受CRS治疗的患者中,47例(74.6%)达到完全肿瘤细胞减灭(CC0/1),术后Clavien-Dindo并发症分级系统Ⅲ、Ⅳ级并发症发生率为17.5%(11/63),无围手术期死亡。生存分析结果显示,CC0/1组的中位PFS时间[22.0个月(95%CI:18.0~67.0个月)比13.0个月(95%CI:3.0个月至未达到),P<0.01]和中位总体生存时间[未达到(95%CI:85.6个月至未达到)比31.5个月(95%CI:25.1个月至未达到),P<0.01]均较CC2/3组有优势。多因素Cox分析结果表明,肿瘤细胞减灭程度是PFS的独立预后因素(HR=5.804,95%CI:1.841~18.296,P<0.01)。 结论: CRS治疗可改善复发和转移性GIST患者的预后,特别是在初次发现复发和转移性肿瘤时。.
引用
- Zhong Y, Zheng QY, Li Y, et al. [Cytoreductive surgery in the management of recurrent or metastatic gastrointestinal stromal tumors: a retrospective analysis from a single-center experience]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41582510. doi:10.3760/cma.j.cn112139-20250616-00302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。